Acorda Therapeutics announced that Inbrija levodopa inhalation powder has been launched in Germany by Esteve Pharmaceuticals. The EMA approved Inbrija DPI for the treatment of OFF periods in Parkinson’s disease in 2019. Acorda said that Esteve will pay "a significant double-digit percent of the selling price" plus sales based milestone payments. In July 2021, … [Read more...] about Esteve Pharmaceuticals launches Inbrija levodopa DPI in Germany
Business
Opiant invests €2 million for expanded production of Aptar nasal device for use with OPNT003
Opiant Pharmaceuticals announced that it has signed an agreement with Aptar Pharma for expanded production of Aptar’s Unidose device in order to support potential commercial demand for Opiant's OPNT003 intranasal nalmefene. The agreement includes €2 million from Opiant for installation of the necessary production equipment. Opiant recently initiated a rolling NDA … [Read more...] about Opiant invests €2 million for expanded production of Aptar nasal device for use with OPNT003
Moderna highlights partnership with Vertex on inhaled mRNA therapy for CF
According to Moderna Therapeutics, the company used its annual "Science and Technology Day" to highlight its work on lipid nanoparticle (LNP) mRNA formulations, and CEO Stéphane Bancel made special note of the company's advances in pulmonary delivery, including a partnership with Vertex on development of an inhaled mRNA formulation that could give CF patients the … [Read more...] about Moderna highlights partnership with Vertex on inhaled mRNA therapy for CF
Spirovant opens new lab and headquarters
Sumitovant subsidiary Spirovant Sciences, which is developing inhaled gene therapies for the treatment of cystic fibrosis, has opened a new research laboratory and corporate headquarters in Philadelphia, PA, USA, the company said. Spirovant's SP-101 inhaled adeno-associated virus (AAV) gene therapy for CF has been granted orphan disease and rare pediatric disease … [Read more...] about Spirovant opens new lab and headquarters
Pieris warns of potential delays in clinical trial of PRS-060/AZD1402 DPI
In a business update, Pieris Pharmaceuticals warned that an ongoing clinical trial of its dry powder PRS-060/AZD1402 IL-4 receptor alpha inhibitor may take longer than expected, saying "Given the geopolitical situation, along with broader challenges amidst an ongoing pandemic, there is a heightened risk that more time will be required to deliver the topline study … [Read more...] about Pieris warns of potential delays in clinical trial of PRS-060/AZD1402 DPI
Evoke gets new drug product exclusivity for Gimoti nasal spray
Evoke Pharma announced that the FDA has granted new drug product exclusivity for Gimoti metoclopramide nasal spray, giving the company exclusive marketing rights for 3 following the initial approval date. The FDA approved Gimoti for the treatment of diabetic gastroparesis in June 2020. The company also noted that it has two patents covering Gimoti listed in the … [Read more...] about Evoke gets new drug product exclusivity for Gimoti nasal spray
Neurelis gets additional patent covering Valtoco nasal spray
According to Neurelis, the US Patent and Trademark Office (USPTO) has issued a new patent covering Valtoco diazepam nasal spray. The abstract for US Patent No. 11,241,414, titled "Administration of benzodiazepine compositions," says that it "relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for … [Read more...] about Neurelis gets additional patent covering Valtoco nasal spray
SK Bioscience partners with IAVI and University of Washington on development of binder protein nasal spray against COVID-19
SK Bioscience announced that it has partnered with nonprofit research organization IAVI on development of an antiviral nasal spray based on a protein developed by David Baker at the University of Washington. The company noted that it will get $2.2 million out of a grant by the Bill & Melinda Gates Foundation to IAVI for the project. The Gates Foundation also … [Read more...] about SK Bioscience partners with IAVI and University of Washington on development of binder protein nasal spray against COVID-19
Receptor Life Sciences raises $9.7 million for development of RLS103 dry powder CBD
Receptor Life Sciences said that it has closed a $9.7 million Series A-1 financing and will use the proceeds for clinical development of its RLS103 cannabidiol DPI. RLS103 is based on MannKind Corporation's Technosphere particle engineering technology, which Receptor licensed for use with its cannabinoid products in 2016. The company is developing the inhaled CBD … [Read more...] about Receptor Life Sciences raises $9.7 million for development of RLS103 dry powder CBD
Gates Foundation provides grant for development of aerosolized surfactant for the treatment of RDS in newborns
The Lundquist Institute for Biomedical Innovation has announced that the Bill & Melinda Gates Foundation has awarded a 2-year grant of $471,858 to principal investigator Frans Walther for further development of an aerosolized synthetic lung surfactant for the treatment of respiratory distress syndrome (RDS) in newborn babies. In March 2021, the institute announced … [Read more...] about Gates Foundation provides grant for development of aerosolized surfactant for the treatment of RDS in newborns